Protagonist Therapeutics stock reached a five-year high of $126.59 on June 29, 2026. As of July 2, 2026, the stock traded at $125.17, having gained 149.29% over the preceding 52 weeks. In the month prior to July 2, 2026, the stock gained 31.87% and made 13 new highs. Between June 11, 2026, and July 2, 2026, the stock increased by 14.01%.

Barchart's Trend Seeker issued a "Buy" signal for the stock on June 11, 2026. Barchart assigns a 100% "Buy" technical opinion to the stock. Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a market capitalization of $7.88 billion. The company utilizes a proprietary technology platform focused on discovering and developing peptide-based new chemical entities.

Technical indicators show a 50-day moving average of $105.19 and a support level around $123.09. The Relative Strength Index (RSI) is 74.06, the 60-month beta is 1.85, and the Weighted Alpha is +121.94.

Wall Street analysts followed by Barchart have assigned 12 "Strong Buy" opinions and 2 "Hold" opinions for the stock, with price targets set between $100 and $137. Analyst projections indicate revenue is expected to decrease by 2.05% in 2026, then increase by 4.17% in 2027. Earnings are estimated to increase by 303.58% in 2026, followed by an estimated decrease of 116.41% in 2027.

Other financial analysis firms have issued different ratings. Value Line rates the stock as "Average," noting low price stability and earnings predictability. CFRA's MarketScope rates the stock as "Hold." Morningstar estimates the fair value at $115, stating the stock is 6% overvalued. Seeking Alpha rates the stock as "Hold," with analysts noting high valuation and low growth and profitability. Short interest stands at 12.02% of the float, with 11.59 days to cover. Jim Van Meerten did not hold positions in Protagonist Therapeutics securities on July 2, 2026.